Advertisement
Full length article| Volume 266, P145-149, November 2021

Download started.

Ok

Evaluation of women referred to the two-week wait gynaecology clinic with suspected ovarian cancer

Published:October 01, 2021DOI:https://doi.org/10.1016/j.ejogrb.2021.09.033
Evaluation of women referred to the two-week wait gynaecology clinic with suspected ovarian cancer
Previous ArticleThe prognostic factors in 384 patients with FIGO 2014 stage IB cervical cancer: What is the role of tumor size on prognosis?
Next ArticleConization and lymph node evaluation in low-risk cervical cancer. Is it time to avoid radical surgery? Retrospective series and literature review

      Abstract

      Objectives

      Ovarian cancer is the leading cause of death from gynaecological cancer in the UK, making early diagnosis key. The two-week wait pathway aims to facilitate rapid referrals from primary to secondary care for suspected cancer thus increasing rates of early diagnosis. The objective of this study was to evaluate referrals made via the two-week wait pathway for suspected ovarian cancer.

      Study Design

      A retrospective analysis of 215 women referred on the two-week wait pathway to a tertiary centre in the United Kingdom with suspected ovarian cancer in 2018.

      Results

      Only 16% of women referred were subsequently diagnosed with gynaecological malignancy. Of those diagnosed with ovarian cancer, 78% had late stage disease at diagnosis. Pre-menopausal women made up 29% of those referred, but only 6% of those diagnosed with cancer.

      Conclusion

      Despite its goal of increasing early stage diagnosis of cancer, the majority of women referred via the two-week wait pathway do not have cancer, and the majority of those who do are referred with late stage disease. These results highlight the need for an effective screening programme for ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Cancer Research UK. Ovarian Cancer Statistics. [Cancer Research UK web site]. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed December 2019.

        View in Article
        • Fagotti A.
        • Ferrandina M.G.
        • Vizzielli G.
        • Pasciuto T.
        • Fanfani F.
        • Gallotta V.
        • et al.
        Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
        Int J Gynecol Cancer. 2020; 30: 1657-1664
        View in Article

      3. NHS England. Achieving World-Class Cancer outcomes: Taking the strategy forward [NHS England web site]. 2016. https://www.england.nhs.uk/wp-content/uploads/2016/05/cancer-strategy.pdf. Accessed December 2019.

        View in Article

      4. National Institute for Health and Care Excellence (2015) Suspected cancer: recognition and referral NICE guideline [NG12] . Available at: https://www.nice.org.uk/guidance/ng12 . Accessed May 2021.

        View in Article
        • Network N.C.I.
        Routes to Diagnosis 2006–2013 workbook (a).
        NCIN, London2015
        View in Article
        • Allgar A.L.
        • Neal R.D.
        • Ali N.
        • et al.
        Variation in ‘fast-track’ referrals for suspected cancer by patient characteristic and cancer diagnosis: evidence from 670 000 patients with cancers of 35 different sites.
        Br J Gen Pract. 2006; 56: 355-362
        View in Article
        • Zhou Y.
        • Mendonca S.C.
        • Abel G.A.
        • Hamilton W.
        • Walter F.M.
        • Johnson S.
        • et al.
        Variation in 'fast-track' referrals for suspected cancer by patient characteristic and cancer diagnosis: evidence from 670 000 patients with cancers of 35 different sites.
        Br J Cancer. 2018; 118: 24-31
        View in Article
        • Chase D.M.
        • Harrow B.
        • Perhanidis J.
        • Monk B.J.
        Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Delays in diagnosis and resulting effects on treatment allocation.
        J Clin Oncol. 2019; 37 (e18195-e18195)
        View in Article
        • Prat J.
        FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
        Int J Gynaecol Obstet. 2014; 124: 1-5
        View in Article

      10. National Cancer Intelligence Network and Cancer Research UK. Routes to diagnosis of cancer by stage, 2012-2013 workbook. London: NCIN; 2016.

        View in Article

      11. Target Ovarian Cancer. Data Briefing on Ovarian Cancer. [Target Ovarian Cancer web site]. 21 December 2018. https://www.targetovariancancer.org.uk/news/new-data-shows-ovarian-cancer-often-spotted-too-late-treatment. Accessed December 2019.

        View in Article
        • Landy R.
        • Pesola F.
        • Castañón A.
        • Sasieni P.
        Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study.
        Br J Cancer. 2016; 115: 1140-1146
        View in Article

      13. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial [published correction appears in Lancet. 2016 Mar 5;387(10022):944] [published correction appears in Lancet. 2016 Mar 5;387(10022):944]. Lancet. 2016;387(10022):945–956.

        View in Article
        • Montagnana M.
        • Benati M.
        • Danese E.
        Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.
        Ann Transl Med. 2017; 5 (276-276)
        View in Article

      15. Department of Health. The NHS cancer plan 2000. Archived. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4014513.pdf. Accessed May 2021.

        View in Article

      Article info

      Publication history

      Published online: October 01, 2021
      Accepted: September 29, 2021
      Received in revised form: September 24, 2021
      Received: June 9, 2021

      Identification

      DOI: https://doi.org/10.1016/j.ejogrb.2021.09.033

      Copyright

      © 2021 Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX